• 1  Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. Lancet 2014;383(9919):816–27. Cross Ref link Pubmed link
  • 2  MacLennan R, Green AC, McLeod G, Martin NG. Increasing incidence of cutaneous melanoma in Queensland, Australia. J Natl Cancer Inst 1992;84:1427–32. Cross Ref link Pubmed link
  • 3  de Vries E, Coebergh JW. Cutaneous malignant melanoma in Europe. Eur J Cancer 2004;40(16):2355–66. Cross Ref link Pubmed link
  • 4  Ferlay J, Steliarova‐Foucher E, Lortet‐Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374–403. Cross Ref link Pubmed link
  • 5  de Vries E, Bray FI, Coebergh JW, Parkin DM. Changing epidemiology of malignant cutaneous melanoma in Europe 1953–1997: rising trends in incidence and mortality but recent stabilizations in western. Europe and decreases in Scandinavia. Int J Cancer 2003;107(1):119–26. Cross Ref link Pubmed link
  • 6  Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. Ed. IARC. CancerBase No. 5 version 2.0. Lyon: IARC Press, 2004.
  • 7  Nikolaou V, Stratigos AJ. Emerging trends in the epidemiology of melanoma. Br J Dermatol 2014;170(1):11–19. Cross Ref link Pubmed link
  • 8  National Cancer Institute. SEER Cancer Statistics Factsheets: Melanoma of the Skin. Bethesda, MD: National Cancer Institute http://seer.cancer.gov/statfacts/html/melan.html (last accessed June 2015).
  • 9  Forsea AM, de Marmol V, de Vries E, et al. Melanoma incidence and mortality in Europe: new estimates, persistent disparities. Br J Dermatol 2012;167:1124–30. Cross Ref link Pubmed link
  • 10  Geller AC, Miller DR, Annas GD, et al. Melanoma incidence and mortality among US whites, 1969–1999. JAMA 2002;288:1719–20. Cross Ref link Pubmed link
  • 11  Marks R. The changing incidence and mortality of melanoma in Australia. Recent Results. Cancer Res 2002;160:113–21.
  • 12  Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol 2009;27(1):3–9. Cross Ref link Pubmed link
  • 13  Purdue MP, Freeman LE, Anderson WF, Tucker MA. Recent trends in incidence of cutaneous melanoma among US Caucasian young adults. J Invest Dermatol 2008;128:2905–8. Cross Ref link Pubmed link
  • 14  Bradford PT, Anderson WF, Purdue MP, et al. Rising melanoma incidence rates of the trunk among younger women in the United States. Cancer Epidemiol Biomarkers Prev 2010;19:2401–6. Cross Ref link Pubmed link
  • 15  Liu F, Bessonova L, Taylor TH, et al. A unique gender difference in early onset melanoma implies that in addition to ultraviolet light exposure other causative factors are important. Pigment Cell Melanoma Res 2013;26:128–35. Cross Ref link Pubmed link
  • 16  Akushevich I, Kravchenko J, Ukraintseva S, et al. Time trends of incidence of age‐associated diseases in the US elderly population: Medicare‐based analysis. Age Ageing 2013;42:494–500. Cross Ref link Pubmed link
  • 17  Baade PD, English DR, Youl PH, et al. The relationship between melanoma thickness and time to diagnosis in a large population‐based study. Arch Dermatol 2006;142:1422–7. Cross Ref link Pubmed link
  • 18  Garbe C, McLeod GR, Buettner PG. Time trends of cutaneous melanoma in Queensland, Australia and Central Europe. Cancer 2000;89:1269–78. Cross Ref link Pubmed link
  • 19  Linos E, Swetter SM, Cockburn MG, et al. Increasing burden of melanoma in the United States. J Invest Dermatol 2009;129:1666–74. Cross Ref link Pubmed link
  • 20  Tryggvadottir L, Gislum M, Hakulinen T, et al. Trends in the survival of patients diagnosed with malignant melanoma of the skin in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol 2010;49:665–72. Cross Ref link Pubmed link
  • 21  Hollestein LM, van den Akker SA, Nijsten T, et al. Trends of cutaneous melanoma in the Netherlands: increasing incidence rates among all Breslow thickness categories and rising mortality rates since 1989. Ann Oncol 2012;23:524–30. Cross Ref link Pubmed link
  • 22  Murray CS, Stockton DL, Doherty VR. Thick melanoma: the challenge persists. Br J Dermatol 2005;152:104–9. Cross Ref link Pubmed link
  • 23  Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013 ;63(1):11–30. Cross Ref link Pubmed link
  • 24  Australian Institute of Health and Welfare. Australian Cancer Incidence and Mortality (ACIM) books http://www.aihw.gov.au/acim‐books/ (last accessed August 2015).
  • 25  Noto G. On the clinical significance of cutaneous melanoma's precursors. Indian Dermatol Online J 2012;3(2):83–8. Cross Ref link Pubmed link
  • 26  Krengel S, Hauschild A, Schäfer T. Melanoma risk in congenital melanocytic naevi: a systematic review. Br J Dermatol 2006;155(1):1–8. Cross Ref link Pubmed link
  • 27  Swerdlow AJ, English JS, Qiao Z. The risk of melanoma in patients with congenital nevi: a cohort study. J Am Acad Dermatol 1995;32(4):595–9. Cross Ref link Pubmed link
  • 28  Tannous ZS, Mihm MC Jr, Sober AJ, Duncan LM. Congenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical management. J Am Acad Dermatol 2005;52(2):197–203. Cross Ref link Pubmed link
  • 29  Ruiz‐Maldonado R, Orozco‐Covarrubias ML. Malignant melanoma in children. A review. Arch Dermatol 1997;133(3):363–71. Cross Ref link Pubmed link
  • 30  Watt AJ, Kotsis SV, Chung KC. Risk of melanoma arising in large congenital melanocytic nevi: a systematic review. Plast Reconstr Surg 2004;113(7):1968–74. Cross Ref link Pubmed link
  • 31  Vourch‐Jourdain M, Martin L, Barbarot S. Large congenital melanocytic nevi: therapeutic management and melanoma risk: a systematic review. J Am Acad Dermatol 2013;68(3):493‐8.e1‐14. Cross Ref link Pubmed link
  • 32  Bauer J, Curtin JA, Pinkel D, Bastian BC. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol 2007;127(1):179–82. Cross Ref link Pubmed link
  • 33  Rhodes AR, Wood WC, Sober AJ, Mihm MC Jr. Nonepidermal origin of malignant melanoma associated with a giant congenital nevocellular nevus. Plast Reconstr Surg 1981;67(6):782–90. Cross Ref link Pubmed link
  • 34  Rhodes AR, Melski JW. Small congenital nevocellular nevi and the risk of cutaneous melanoma. J Pediatr 1982;100(2):219–24. Cross Ref link Pubmed link
  • 35  Tsao H, Bevona C, Goggins W, Quinn T. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population‐based estimate. Arch Dermatol 2003;139(3):282–8. Cross Ref link Pubmed link
  • 36  National Institute of Health (NIH). Diagnosis and treatment of early melanoma. NIH Consensus Development Conference. Consensus Statement 1992 Jan 27–29;10(1):1–25.
  • 37  Crutcher WA, Sagebiel RW. Prevalence of dysplastic naevi in a community practice. Lancet 1984;1:729. Cross Ref link Pubmed link
  • 38  Clark WH, Elder DE, Guerry D, et al. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984;15:1147–65. Cross Ref link Pubmed link
  • 39  Kath R, Rodeck U, Menssen HD, et al. Tumor progression in the human melanocytic system. Anticancer Res 1989;9(4):865–72. Pubmed link
  • 40  Bataille V, Bishop JA, Sasieni P, et al. Risks of cutaneous melanoma in relation to the numbers, types, and sites of naevi: A case–control study. Br J Cancer 1996;73:1605–11. Cross Ref link Pubmed link
  • 41  Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi: A central risk factor for cutaneous melanoma. JAMA 1997;277:1439–44. Cross Ref link Pubmed link
  • 42  Reddy KK, Farber MJ, Bhawan J, et al. Atypical (dysplastic) nevi: outcomes of surgical excision and association with melanoma. JAMA Dermatol 2013;149(8):928–34. Cross Ref link Pubmed link
  • 43  Olsen CM, Carroll HJ, Whiteman DC. Familial melanoma: a meta‐analysis and estimates of attributable fraction. Cancer Epidemiol Biomarkers Prev 2010;19(1):65–73. Cross Ref link Pubmed link
  • 44  Fitzpatrick TB. The validity and practicality of sun‐reactive skin types I through VI. Arch Dermatol 1988;124(6):869–71. Cross Ref link Pubmed link
  • 45  Gandini S, Sera F, Cattaruzza MS, et al. Meta‐analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005;41(14):2040–59. Cross Ref link Pubmed link
  • 46  Grob JJ, Gouvernet J, Aymar D, et al. Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma. Cancer 1990;66(2):387–95. Cross Ref link Pubmed link
  • 47  Richard MA, Grob JJ, Gouvernet J, et al. Role of sun exposure on nevus. First study in age‐sex phenotype‐controlled populations. Arch Dermatol 1993;129(10):1280–5. Cross Ref link Pubmed link
  • 48  Clark WH Jr, Reimer RR, Greene M, et al. Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B‐K mole syndrome'. Arch Dermatol 1978;114(5):732–8. Cross Ref link Pubmed link
  • 49  Greene MH, Clark WH Jr, Tucker MA, et al. Precursor naevi in cutaneous malignant melanoma: a proposed nomenclature. Lancet 1980;2:1024. Cross Ref link Pubmed link
  • 50  Greene MH, Clark WH Jr, Tucker MA, et al. High risk of malignant melanoma in melanoma‐prone families with dysplastic nevi. Ann Intern Med 1985;102:458–65. Cross Ref link Pubmed link
  • 51  Newton JA, Bataille V, Griffiths K, et al. How common is the atypical mole syndrome phenotype in apparently sporadic melanoma? J Am Acad Dermatol 1993;29(6):989–96. Cross Ref link Pubmed link
  • 52  Gandini S, Sera F, Cattaruzza MS, et al. Meta‐analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005;41(1):28–44. Cross Ref link Pubmed link
  • 53  Tucker MA, Fraser MC, Goldstein AM, et al. Risk of melanoma and other cancers in melanoma‐prone families. J Invest Dermatol 1993;100(3):350S–5S. Cross Ref link Pubmed link
  • 54  Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF‐INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998;92(6):725–34. Cross Ref link Pubmed link
  • 55  Yeh I, Bastian BC. Genome‐wide associations studies for melanoma and nevi. Pigment Cell Melanoma Res 2009;22(5):527–8. Cross Ref link Pubmed link
  • 56  Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma‐prone kindreds with p16INK4 mutations. N Engl J Med 1995;12;333(15):970–4. Cross Ref link Pubmed link
  • 57  Goldstein AM, Chan M, Harland M, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma‐prone families from three continents. J Med Genet 2007;44(2):99–106. Cross Ref link Pubmed link
  • 58  Ghiorzo P, Ciotti P, Mantelli M, et al. Characterization of ligurian melanoma families and risk of occurrence of other neoplasia. Int J Cancer 1999;83(4):441–8 Cross Ref link Pubmed link
  • 59  Monzon J, Liu L, Brill H, et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med 1998;26;338(13):879–87. Cross Ref link Pubmed link
  • 60  Auroy S, Avril MF, Chompret A, et al. French Hereditary Melanoma Study Group. Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect. Genes Chromosomes Cancer 2001;32(3):195–202. Cross Ref link Pubmed link
  • 61  Bishop DT, Demenais F, Goldstein AM, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002 19;94(12):894–903. Cross Ref link Pubmed link
  • 62  Chaudru V, Chompret A, Bressac‐de Paillerets B, et al. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma‐prone families. J Natl Cancer Inst 2004;19;96(10):785–95. Cross Ref link Pubmed link
  • 63  Ward KA, Lazovich D, Hordinsky MK. Germline melanoma susceptibility and prognostic genes: a review of the literature. J Am Acad Dermatol 2012;67(5):1055–67. Cross Ref link Pubmed link
  • 64  Soufir N, Avril MF, Chompret A, et al. Prevalence of p16 and CDK4 germline mutations in 48 melanoma‐prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 1998;7(2):209–16.
  • 65  Zuo L, Weger J, Yang Q, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996;12(1):97–9. Cross Ref link Pubmed link
  • 66  Pjanova D, Molven A, Akslen LA, et al. Identification of a CDK4 R24H mutation‐positive melanoma family by analysis of early‐onset melanoma patients in Latvia. Melanoma Res 2009;19(2):119–22. Cross Ref link Pubmed link
  • 67  Chatzinasiou F, Lill CM, Kypreou K, et al. Comprehensive field synopsis and systematic meta‐analyses of genetic association studies in cutaneous melanoma. J Natl Cancer Inst 2011;17;103(16):1227–35. Cross Ref link Pubmed link
  • 68  Valverde P, Healy E, Jackson I, et al. Variants of the melanocyte‐stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995;11(3):328–30. Cross Ref link Pubmed link
  • 69  Valverde P, Healy E, Sikink S, et al. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet 1996;5:1663–6. Cross Ref link Pubmed link
  • 70  Kennedy C, ter Huurne J, Berkhout M, et al. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 2001;117(2):294–300. Cross Ref link Pubmed link
  • 71  Box NF, Duffy DL, Chen W, et al. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 2001;69(4):765–73. Cross Ref link Pubmed link
  • 72  Goldstein AM, Landi MT, Tsang S, et al. Association of MC1R variants and risk of melanoma in melanoma‐prone families with CDKN2A mutations. Cancer Epidemiol Biomarkers Prev 2005;14(9):2208–12. Pubmed link
  • 73  Nan H, Kraft P, Hunter DJ, Han J. Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians. Int J Cancer 2009;125(4):909–17. Cross Ref link Pubmed link
  • 74  Maccioni L, Rachakonda PS, Scherer D, et al. Variants at chromosome 20 (ASIP locus) and melanoma risk. Int J Cancer 2013;Jan 1;132(1):42–54. Cross Ref link Pubmed link
  • 75  Brown KM, Macgregor S, Montgomery GW, et al. Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet 2008;40(7):838–40. Cross Ref link Pubmed link
  • 76  Sulem P, Gudbjartsson DF, Stacey SN, et al. Two newly identified genetic determinants of pigmentation in Europeans. Nat Genet 2008;40(7):835–7. Cross Ref link Pubmed link
  • 77  Fernandez LP, Milne RL, Pita G, et al. SLC45A2: a novel malignant melanoma‐associated gene. Hum Mutat 2008;29:1161–7. Cross Ref link Pubmed link
  • 78  Bishop DT, Demenais F, Iles MM, et al. Genome‐wide association study identifies three loci associated with melanoma risk. Nat Genet 2009;41:920–8. Cross Ref link Pubmed link
  • 79  Fernandez LP, Milne RL, Pita G, et al. Pigmentation‐related genes and their implication in malignant melanoma susceptibility. Exp Dermatol 2009;18:634–42. Cross Ref link Pubmed link
  • 80  Duffy DL, Zhao ZZ, Sturm RA, et al. Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma. J Invest Dermatol 2010;130(2):520–8. Cross Ref link Pubmed link
  • 81  Cheli Y, Ohanna M, Ballotti R, Bertolotto C. Fifteen‐year quest for microphthalmia‐associated transcription factor target genes. Pigment Cell Melanoma Res 2010;23(1):27–40. Cross Ref link Pubmed link
  • 82  Liu F, Fu Y, Meyskens FL Jr. MiTF regulates cellular response to reactive oxygen species through transcriptional regulation of APE‐1/Ref‐1. J Invest Dermatol 2009;129(2):422–31. Cross Ref link Pubmed link
  • 83  Yokoyama S, Woods SL, Boyle GM, et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011;480(7375):99–103. Cross Ref link Pubmed link
  • 84  Bertolotto C, Lesueur F, Giuliano S, et al. A SUMOylation‐defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 2011;480:94–8. Cross Ref link Pubmed link
  • 85  Ghiorzo P, Pastorino L, Queirolo P, et al. Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history. Pigment Cell Melanoma Res 2013;26(2):259–62. Cross Ref link Pubmed link
  • 86  Carbone M, Ferris LK, Baumann F, et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med 2012;10:179. Cross Ref link Pubmed link
  • 87  Njauw CN, Kim I, Piris A, et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous‐ocular melanoma families. PLOS One 2012;7(4):e35295. Cross Ref link Pubmed link
  • 88  Mocellin S, Verdi D, Nitti D. DNA repair gene polymorphisms and risk of cutaneous melanoma: a systematic review and meta‐analysis. Carcinogenesis 2009;30(10):1735–43. Cross Ref link Pubmed link
  • 89  Figl A, Scherer D, Nagore E, et al. Single‐nucleotide polymorphisms in DNA‐repair genes and cutaneous melanoma. Mutat Res 2010;30;702(1):8–16. Cross Ref link Pubmed link
  • 90  Figl A, Scherer D, Nagore E, et al. Single nucleotide polymorphisms in DNA repair genes XRCC1 and APEX1 in progression and survival of primary cutaneous melanoma patients. Mutat Res 2009;10;661(1–2):78–84. Cross Ref link Pubmed link
  • 91  Liu D, O'Day SJ, Yang D, et al. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study. Clin Cancer Res 2005;1;11(3):1237–46. Pubmed link
  • 92  Gandini S, Raimondi S, Gnagnarella P, et al. Vitamin D and skin cancer: a meta‐analysis. Eur J Cancer 2009;45(4):634–41. Cross Ref link Pubmed link
  • 93  Santonocito C, Capizzi R, Concolino P, et al. Association between cutaneous melanoma, Breslow thickness and vitamin D receptor BsmI polymorphism. Br J Dermatol 2007;156(2):277–82. Cross Ref link Pubmed link
  • 94  Gandini S, Sera F, Cattaruzza MS, et al. Meta‐analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005;41(1):45–60. Cross Ref link Pubmed link
  • 95  Oliveria SA, Saraiya M, Geller AC, et al. Sun exposure and risk of melanoma. Arch Dis Child 2006;91(2):131–8. Cross Ref link Pubmed link
  • 96  Cust AE, Jenkins MA, Goumas C, et al. Early‐life sun exposure and risk of melanoma before age 40 years. Cancer Causes Control 2011;22(6):885–97. Cross Ref link Pubmed link
  • 97  Whiteman DC, Stickley M, Watt P, et al. Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol 2006;24(19):3172–7. Cross Ref link Pubmed link
  • 98  Holman CD, Armstrong BK, Heenan PJ. Relationship of cutaneous malignant melanoma to individual sunlight‐exposure habits. J Natl Cancer Inst 1986;76(3):403–14. Pubmed link
  • 99  Whiteman DC, Valery P, McWhirter W, Green AC. Risk factors for childhood melanoma in Queensland, Australia. Int J Cancer 1997;70(1):26–31. Cross Ref link Pubmed link
  • 100  Anderson WF, Pfeiffer RM, Tucker MA, Rosenberg PS. Divergent cancer pathways for early‐onset and late‐onset cutaneous malignant melanoma. Cancer 2009;115(18):4176–85. Cross Ref link Pubmed link
  • 101  Walter SD, King WD, Marrett LD. Association of cutaneous malignant melanoma with intermittent exposure to ultraviolet radiation: results of a case–control study in Ontario, Canada. Int J Epidemiol 1999;28(3):418–27. Cross Ref link Pubmed link
  • 102  Pleasance ED, Cheetham RK, Stephens PJ, et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010;463(7278):191–6. Cross Ref link Pubmed link
  • 103  Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell 2012;150:251–63. Cross Ref link Pubmed link
  • 104  Berger MF, Hodis E, Heffernan TP, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012;9;485(7399):502–6.
  • 105  Pavey S, Spoerri L, Haass NK, Gabrielli B. DNA repair and cell cycle checkpoint defects as drivers and therapeutic targets in melanoma. Pigment Cell Melanoma Res 2013;26(6):805–16. Cross Ref link Pubmed link
  • 106  Gilchrest BA, Eller MS, Geller AC, Yaar M. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 1999;340(17):1341–8. Cross Ref link Pubmed link
  • 107  Van Schanke A, van Venrooij GM, Jongsma MJ, et al. Induction of nevi and skin tumors in Ink4a/Arf Xpa knockout mice by neonatal, intermittent, or chronic UVB exposures. Cancer Res 2006;Mar 1;66(5):2608–15. Cross Ref link Pubmed link
  • 108  Bailey EC, Sober AJ, Tsao H, et al. Cutaneous melanoma. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, eds. Fitzpatrick's Dermatology in General Medicine. New York: McGraw‐Hill, 2012:1416–44.
  • 109  Whiteman DC, Whiteman CA, Green AC. Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control 2001;12:69–82. Cross Ref link Pubmed link
  • 110  Gaudy‐Marqueste C, Madjlessi N, Guillot B, et al. Risk factors in elderly people for lentigo maligna compared with other melanomas: a double case–control study. Arch Dermatol 2009;145(4):418–23. Pubmed link
  • 111  Holman CD, Armstrong BK. Cutaneous malignant melanoma and indicators of total accumulated exposure to the sun: an analysis reporting histogenetic types. J Natl Cancer Inst 1984;73:75–82. Pubmed link
  • 112  Movshovitz M, Modan B. Role of sun exposure in the etiology of malignant melanoma: epidemiologic inference. J Natl Cancer Inst 1973;51(3):777–9. Pubmed link
  • 113  Autier P, Dore JF, Gefeller O, et al. Melanoma risk and residence in sunny areas. EORTC Melanoma Co‐operative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 1997;76:1521–4. Cross Ref link Pubmed link
  • 114  Levine H, Afek A, Shamiss A, et al. Country of origin, age at migration and risk of cutaneous melanoma: a migrant cohort study of 1,100,000 Israeli men. Int J Cancer 2013;15;133(2):486–94. Cross Ref link Pubmed link
  • 115  Weinstock MA, Colditz GA, Willett WC, et al. Nonfamilial cutaneous melanoma incidence in women associated with sun exposure before 20 years of age. Pediatrics 1989;84(2):119–204. Pubmed link
  • 116  Osterlind MA, Tucker BJ, Stone OM. The Danish case–control study of cutaneous malignant melanoma. II. Importance of UV‐light exposure. Int J Cancer 1988;45(3):319–24. Cross Ref link
  • 117  Dennis LK, Vanbeek MJ, Beane Freeman LE, et al. Sunburns and risk of cutaneous melanoma: does age matter? A comprehensive meta‐analysis. Ann Epidemiol 2008;18(8):614–27. Cross Ref link Pubmed link
  • 118  Gallagher RP, Spinelli JJ, Lee TK. Tanning beds, sunlamps, and risk of cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 2005;14(3):562–6. Cross Ref link Pubmed link
  • 119  Bataille V, Boniol M, De Vries E, et al. A multicentre epidemiological study on sunbed use and cutaneous melanoma in Europe. Eur J Cancer 2005;41(14):2141–9. Cross Ref link Pubmed link
  • 120  de Vries E, Boniol M, Severi G, et al. Public awareness about risk factors could pose problems for case–control studies: the example of sunbed use and cutaneous melanoma. Eur J Cancer 2005;41(14):2150–4. Cross Ref link Pubmed link
  • 121  Han J, Colditz GA, Hunter DJ. Risk factors for skin cancers: a nested case–control study within the nurses' health study. Int J Epidemiol 2006;35(6),1514–21. Cross Ref link Pubmed link
  • 122  Ting W, Schultz K, Cac NN, et al. Tanning bed exposure increases the risk of malignant melanoma. Int J Epidemiol 2007;46(12):1253–7.
  • 123  Gandini S, Autier P, Boniol M. Reviews on sun exposure and artificial light and melanoma. Prog Biophys Mol Biol 2011;Dec;107(3):362–6. Cross Ref link Pubmed link
  • 124  Boniol M, Autier P, Boyle P, Gandini S. Cutaneous melanoma attributable to sunbed use: systematic review and meta‐analysis. BMJ 2012;345:e4757. Cross Ref link Pubmed link
  • 125  Rhodes AR, Harrist TJ, Momtaz TK. The PUVA‐induced pigmented macule: a lentiginous proliferation of large, sometimes cytologically atypical, melanocytes. J Am Acad Dermatol 1983;9:47–58. Cross Ref link Pubmed link
  • 126  Alcaly J, Bucana C, Kripke ML. Cutaneous pigmented melanocytic tumor in a mouse treated with psoralen plus ultraviolet A radiation. Photodermatol Photoimmunol Photomed 1990;7:28–31. Pubmed link
  • 127  Aubin F, Donawho CK, Kripke ML. Effect of psoralen plus ultraviolet A radiation on in vivo growth of melanoma cells. Cancer Res 1991;51:589–7.
  • 128  Lindelöf B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer risk: the Swedish follow‐up study. Br J Dermatol 1999;Jul;141(1):108–12. Cross Ref link Pubmed link
  • 129  Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA follow‐up study. N Engl J Med 1997;336:1041–5. Cross Ref link Pubmed link
  • 130  Stern RS; PUVA Follow up Study. The risk of melanoma in association with long‐term exposure to PUVA. J Am Acad Dermatol 2001;44(5):755–61. Cross Ref link Pubmed link
  • 131  BruynzeelI I, Bergman W, Hartevelt HM, et al. ‘High single‐dose’ European PUVA regimen also causes an excess of non‐melanoma skin cancer. Br J Dermatol 1991;124:49–55. Cross Ref link Pubmed link
  • 132  Hannuksela‐Svahn A, Pukkala E, Läärä E, et al. Psoriasis, its treatment, and cancer in a cohort of Finnish Patients. J Invest Dermatol 2000;114:587–90. Cross Ref link Pubmed link
  • 133  Archier E, Devaux S, Castela E, et al. Carcinogenic risks of psoralen UV‐A therapy and narrowband UV‐B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012;26 Suppl. 3:22–31. Cross Ref link Pubmed link
  • 134  Weischer M, Blum A, Eberhard F, et al. No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study. Acta Derm Venereol 2004;84:370–4. Cross Ref link Pubmed link
  • 135  Man I, Crombie IK, Dawe RS, et al. The photocarcinogenic risk of narrowband UVB (TL‐01) phototherapy: early follow‐up data. Br J Dermatol 2005;152:755–7. Cross Ref link Pubmed link
  • 136  Black RJ, Gavin AT. Photocarcinogenic risk of narrowband ultraviolet B (TL‐01) phototherapy: early follow‐up data. Br J Dermatol 2006;154:566–7. Cross Ref link Pubmed link
  • 137  Hearn RM, Kerr AC, Rahim KF, et al. Incidence of skin cancers in 3867 patients treated with narrow‐band ultraviolet B phototherapy. Br J Dermatol 2008;159:931–5. Cross Ref link Pubmed link
  • 138  Leachman SA, Carucci J, Kohlmann W, et al. Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol 2009;61(4):677.e1–14. Cross Ref link
  • 139  Kefford R, Bishop JN, Tucker M, et al. Genetic testing for melanoma. Lancet Oncol 2002;3(11):653–4. Cross Ref link Pubmed link
  • 140  Ferlay J, Shin HR, Bray C, et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 10 [internet]. International Agency for Research on Cancer, 2010, Lyon, France
  • 141  Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma risk after regular sunscreen use: randomized trial follow‐up. J Clin Oncol 2011;29(3):257–63. Cross Ref link Pubmed link
  • 142  Bauer J, Büttner P, Wiecker TS, et al. Interventional study in 1,232 young German children to prevent the development of melanocytic nevi failed to change sun exposure and sun protective behavior. Int J Cancer 2005;116(5)755:61. Cross Ref link Pubmed link
  • 143  Nicol I, Gaudy C, Gouvernet J, et al. Skin protection by sunscreens is improved by explicit labeling and providing free sunscreen. J Invest Dermatol 2007;127(1):41–8. Cross Ref link Pubmed link
  • 144  Madhunapantula SV, Robertson GP. Chemoprevention of melanoma. Adv Pharmacol 2012;65:361–98. Cross Ref link Pubmed link
  • 145  MacKie RM, Freudenberger T, Aitchison TC. Personal risk‐factor chart for cutaneous melanoma. Lancet 1989;2(8661):487–90. Cross Ref link Pubmed link
  • 146  Newton JA, Bataille V, Griffiths K, et al. How common is the atypical mole syndrome phenotype in apparently sporadic melanoma? J Am Acad Dermatol 1993;29(6):989–96. Cross Ref link Pubmed link
  • 147  Cho E, Rosner BA, Feskanich D, Colditz GA. Risk factors and individual probabilities of melanoma for whites. J Clin Oncol 2005;23(12):2699–75.
  • 148  Goldberg MS, Doucette JT, Lim HW, et al. Risk factors for presumptive melanoma in skin cancer screening: American Academy of Dermatology National Melanoma/Skin Cancer Screening Program experience 2001–2005. J Am Acad Dermatol 2007;57:60–6. Cross Ref link Pubmed link
  • 149  Gimotty PA, Elder DE, Fraker DL, et al. Identification of high‐risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 2007;25(9):1129–34. Cross Ref link Pubmed link
  • 150  McGovern VJ, Mihm MC, Bailly C, et al. The classification of malignant melanoma and its histologic reporting. Cancer 1973;32:1446–57. Cross Ref link Pubmed link
  • 151  Elder DE, Guerry D 4th, Epstein MN, et al. Invasive malignant melanomas lacking competence for metastasis. Am J Dermatopathol 1984;Summer;6 Suppl.:55–61. Pubmed link
  • 152  Whiteman DC, Parsons PG, Green AC. p53 expression and risk factors for cutaneous melanoma: a case–control study. Int J Cancer 1998;77(6):843–8. Cross Ref link Pubmed link
  • 153  Whiteman DC, Watt P, Purdie DM, et al. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003;95:806–12. Cross Ref link Pubmed link
  • 154  Whiteman DC, Pavan WJ, Bastian BC. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res 2011;24(5):879–97. Cross Ref link Pubmed link
  • 155  Grob JJ, Richard MA, Gouvernet J, et al. The kinetics of the visible growth of a primary melanoma reflects the tumor aggressiveness and is an independent prognostic marker: a prospective study. Int J Cancer 2002;102(1):34–8. Cross Ref link Pubmed link
  • 156  Liu W, Dowling JP, Murray WK, et al. Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol 2006;142(12):1551–8. Pubmed link
  • 157  Martorell‐Calatayud A, Nagore E, Botella‐Estrada R, Scherer D. Defining fast‐growing melanomas: reappraisal of epidemiological, clinical, andhistological features. Melanoma Res 2011;21(2):131–8. Cross Ref link Pubmed link
  • 158  Tejera‐Vaquerizo A, Barrera‐Vigo MV, López‐Navarro N, Herrera‐Ceballos E. Growth rate as a prognostic factor in localized invasive cutaneous melanoma. J Eur Acad Dermatol Venereol 2010;24(2):147–54. Cross Ref link Pubmed link
  • 159  Tejera‐Vaquerizo A, Nagore E, Herrera‐Acosta E, et al. Prediction of sentinel lymph node positivity by growth rate of cutaneous melanoma. Arch Dermatol 2012;148(5):577–84. Pubmed link
  • 160  Liu W, McArthur GA, Trivett M, et al. Correlation of subjective self‐reported melanoma growth rate with objective tumor proliferation markers. Arch Dermatol 2008;144(4):555–6. Pubmed link
  • 161  Nagore E, Hacker E, Martorell‐Calatayud A, et al. Prevalence of BRAF and NRAS mutations in fast‐growing melanomas. Pigment Cell Melanoma Res 2013;26(3):429–31. Cross Ref link Pubmed link
  • 162  Curtin JA, Fridlyand J, Kageshita T, Patel HN. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353(20):2135–47. Cross Ref link Pubmed link
  • 163  Davies H, Bignell GR, Cox C, Stephens P. Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949–54. Cross Ref link Pubmed link
  • 164  Scolyer RA, Long GV, Thompson JF. Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Mol Oncol 2011;5(2):124–36. Cross Ref link Pubmed link
  • 165  Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: A meta‐analysis. Br J Dermatol 2011;164:776–84. Cross Ref link Pubmed link
  • 166  Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340–6. Cross Ref link Pubmed link
  • 167  Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009;457:599–602. Cross Ref link Pubmed link
  • 168  Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010;363:2191–9. Cross Ref link Pubmed link
  • 169  Broekaert SM, Roy R, Okamoto I, et al. Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res 2010;23:763–70. Cross Ref link Pubmed link
  • 170  Viros A, Fridlyand J, Bauer J, et al. Bastian Improving melanoma classification by integrating genetic and morphologic features. PLOS Med 2008;5:e120. Cross Ref link Pubmed link
  • 171  McCarthy JT. ABCDs of melanoma. Cutis 1995;56(6):313. Pubmed link
  • 172  MacKie RM. Clinical recognition of early invasive malignant melanoma. BMJ 1990;301(6759):1005–6. Cross Ref link Pubmed link
  • 173  Gachon J, Beaulieu P, Sei JF, et al. First prospective study of the recognition process of melanoma in dermatological practice. Arch Dermatol 2005;141(4):434–8. Cross Ref link Pubmed link
  • 174  Girardi S, Gaudy C, Gouvernet J, et al. Superiority of a cognitive education with photographs over ABCD criteria in the education of the general population to the early detection of melanoma: a randomized study. Int J Cancer 2006;118:2276–80. Cross Ref link Pubmed link
  • 175  Grob JJ, Bonerandi JJ. The 'ugly duckling' sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol 1998;134(1):103–4. Cross Ref link Pubmed link
  • 176  Wazaefi Y, Gaudy‐Marqueste C, Avril MF, et al. Evidence of a limited intra‐individual diversity of nevi: intuitive perception of dominant clusters is a crucial step in the analysis of nevi by dermatologists. J Invest Dermatol 2013;133(10):2355–61. Cross Ref link Pubmed link
  • 177  Mayer J. Systematic review of the diagnostic accuracy of dermatoscopy in detecting malignant melanoma. Med J Aust 1997;167(4):206–10. Pubmed link
  • 178  Pellacani G, Cesinaro AM, Seidenari S. Reflectance‐mode confocal microscopy of pigmented skin lesions – improvement in melanoma diagnostic specificity. J Am Acad Dermatol 2005;53(6):979–85. Cross Ref link Pubmed link
  • 179  Segura S, Puig S, Carrera C, Palou J, Malvehy J. Development of a two‐step method for the diagnosis of melanoma by reflectance confocal microscopy. J Am Acad Dermatol 2009;61(2):216–29. Cross Ref link Pubmed link
  • 180  McLaughlin CC, Wu XC, Jemal A, et al. Incidence of non cutaneous melanomas in the US. Cancer 2005;103(5):1000–7. Cross Ref link Pubmed link
  • 181  Isager P, Engholm G, Overgaard J, Storm H. Uveal and conjunctival malignant melanoma in denmark 1943–97: observed and relative survival of patients followed through 2002. Ophthalmic Epidemiol 2006;13(2):85–96. Cross Ref link Pubmed link
  • 182  Anastassiou G, Heiligenhaus A, Bechrakis N, et al. Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study. Br J Ophthalmol 2002;86(2):163–7. Cross Ref link Pubmed link
  • 183  Kamposioras, Pentheroudakis G, Pectasides D, Pavlidis N. Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature. Crit Rev Oncol Hematol 2011;78(2):112–26. Cross Ref link Pubmed link
  • 184  Cormier JN, Xing Y, Feng L, et al. Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer 2006;106(9):2012–20. Cross Ref link Pubmed link
  • 185  Anbari KK, Schuchter LM, Bucky LP, et al. Melanoma of unknown primary site: presentation, treatment, and prognosis — A single institution study. Cancer 1997;79:1816–21. Cross Ref link Pubmed link
  • 186  Richard MA, Grob JJ, Avril MF, et al. Melanoma and tumor thickness: challenges of early diagnosis. Arch Dermatol 1999;135(3):269–74. Cross Ref link Pubmed link
  • 187  Krige JE, Isaacs S, Hudson DA, et al. Delay in the diagnosis of cutaneous malignant melanoma. A prospective study in 250 patients. Cancer 1991;68(9):2064–8. Cross Ref link Pubmed link
  • 188  Tyler I, Rivers JK, Shoveller JA, Blum A. Melanoma detection in British Columbia, Canada. J Am Acad Dermatol 2005;52(1):48–54. Cross Ref link Pubmed link
  • 189  Baumert J, Plewig G, Volkenandt M, et al. Factors associated with a high tumour thickness in patients with melanoma. Br J Dermatol 2007;156(5):938–44. Cross Ref link Pubmed link
  • 190  Akushevich I, Kravchenko J, Ukraintseva S, et al. Time trends of incidence of age‐associated diseases in the US elderly population: Medicare‐based analysis. Age Ageing 2013;42:494–500. Cross Ref link Pubmed link
  • 191  Geller AC, Elwood M, Swetter SM, et al. Factors related to the presentation of thin and thick nodular melanoma from a population based cancer registry in Queensland Australia. Cancer 2009;115:1318–27. Cross Ref link Pubmed link
  • 192  Geller J, Swetter SM, Leyson J, et al. Crafting a melanoma educational campaign to reach middle‐aged and older men. J Cutan Med Surg 2006;10(6):259–68. Cross Ref link Pubmed link
  • 193  Carli P, De Giorgi V, Palli D, et al. Dermatologist detection and skin self‐examination are associated with thinner melanomas: results from a survey of the Italian Multidisciplinary Group on Melanoma. Arch Dermatol 2003;139(5):607–12. Cross Ref link Pubmed link
  • 194  Pollitt RA, Geller AC, Brooks DR, et al. Efficacy of skin self‐examination practices for early melanoma detection. Cancer Epidemiol Biomarkers Prev 2009;18(11):3018–23. Cross Ref link Pubmed link
  • 195  Breitbart EW, Waldmann A, Nolte S, et al. Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol 2012;66(2):201–11. Cross Ref link Pubmed link
  • 196  MacKie RM, Bray CA, Leman JA. Effect of public education aimed at early diagnosis of malignant melanoma: cohort comparison study. BMJ 2003;326:367. Cross Ref link Pubmed link
  • 197  Grob JJ. Cost‐effectiveness in skin cancer prevention In: Altmeyer P, Hoffmann K, Stucker M, eds. Skin Cancer and UV Radiation. Berlin: Springer‐Verlag, 1997.
  • 198  Richard MA, Grob JJ, Avril MF, et al. Delays in diagnosis and melanoma prognosis (I): the role of patients. Int J Cancer 2000;89:271–9. Cross Ref link Pubmed link
  • 199  Richard MA, Grob JJ, Avril MF, et al. Delays in diagnosis and melanoma prognosis (II): the role of doctors. Int J Cancer 2000;89:280–5. Cross Ref link Pubmed link
  • 200  Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: the role of physician examination and self‐examination of the skin. CA Cancer J Clin 1985;35:130–51. Cross Ref link Pubmed link
  • 201  Gaudy‐Marqueste C, Dubois M, Richard MA, et al. Cognitive training with photographs as a new concept in an education campaign for self‐detection of melanoma: a pilot study in the community. J Eur Acad Dermatol Venereol 2011;25(9):1099–103. Cross Ref link Pubmed link
  • 202  Barnhill RL, Mihm MC. Histopathology and precursor lesions. In: Balch CM, Houghton AN, Sober AJ, Soong SJ, eds. Cutaneous Melanoma. St Louis, Missouri: Quality Medical Publishing, 1998:65–79.
  • 203  Smoller BR. Histologic criteria for diagnosing primary cutaneous malignant melanoma. Mol Pathol 2006;19 Suppl. 2:S34–40. Cross Ref link
  • 204  Barnhill RL. Pathology of Melanocytic Nevi and Malignant Melanoma. Boston: Butterworth‐Heinemann, 1995.
  • 205  Barnhill RL, Mihm MC Jr. The histopathology of cutaneous malignant melanoma. Semin Diagn Pathol 1993;10(1):47–75. Pubmed link
  • 206  Elder D, Elenitsas R. Benign pigmented lesions and malignant melanoma. In: Elder E, Elenitsas R, Jaworsky C, Johnson B , eds. Lever's Histopathology of the Skin, 8th edn. Philadelphia: Lippincott‐Raven, 1997:625–84.
  • 207  Schmoeckel C, Castro CE, Braun‐Falco O. Nevoid malignant melanoma. Arch Dermatol Res 1985;277(5):362–9. Cross Ref link Pubmed link
  • 208  Cerroni L, Barnhill R, Elder D, et al. Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz 2008. Am J Surg Pathol 2010;34:314–26. Cross Ref link Pubmed link
  • 209  LeBoit PE. A diagnosis for maniacs. Am J Dermatopathol 2000;22(6):556–8. Cross Ref link Pubmed link
  • 210  Conley J, Lattes R, Orr W. Desmoplastic malignant melanoma (a rare variant of spindle cell melanoma). Cancer 1971;28(4):914–36. Cross Ref link Pubmed link
  • 211  Kamino H. Spitzoid melanoma. Clin Dermatol 2009;27(6):545–55. Cross Ref link Pubmed link
  • 212  Barnhill RL, Gupta K. Unusual variants of malignant melanoma. Clin Dermatol 2009;27(6):564–87. Cross Ref link Pubmed link
  • 213  Nakajima T, Watanabe S, Sato Y, et al. Immunohistochemical demonstration of S100 protein in malignant melanoma and pigmented nevus, and its diagnostic application. Cancer 1982;50(5):912–18. Cross Ref link Pubmed link
  • 214  Fernando SS, Johnson S, Bäte J. Immunohistochemical analysis of cutaneous malignant melanoma: comparison of S‐100 protein, HMB‐45 monoclonal antibody and NKI/C3 monoclonal antibody. Pathology 1994;26(1):16–19. Cross Ref link Pubmed link
  • 215  Blokx WA, van Dijk MC, Ruiter DJ. Molecular cytogenetics of cutaneous melanocytic lesions – diagnostic, prognostic and therapeutic aspects. Histopathology 2010;56(1):121–32. Cross Ref link Pubmed link
  • 216  Braun‐Falco M, Schempp W, Weyers W. Molecular diagnosis in dermatopathology: what makes sense, and what doesn't. Exp Dermatol 2009;18(1):12–23. Cross Ref link Pubmed link
  • 217  Pfeifer JD. Molecular pathology and patient care. Mol Med 2010;107(2):86–93.
  • 218  Gerami P, Jewell SS, Morrison LE, et al. Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol 2009;33(8):1146–56. Cross Ref link Pubmed link
  • 219  Senetta R, Paglierani M, Massi D. Fluorescence in‐situ hybridization analysis for melanoma diagnosis. Histopathology 2012;60(5):706–14. Cross Ref link Pubmed link
  • 220  Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 1978;135(6):807–10. Cross Ref link Pubmed link
  • 221  Fusi, Ariyan S, Sternlicht A. Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast Reconstr Surg 1993;91(1):94–8. Cross Ref link Pubmed link
  • 222  de la Monte SM, Moore GW, Hutchins GM. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res 1983;43(7):3427–33. Pubmed link
  • 223  Soong SJ, Shaw HM, Balch CM, et al. Predicting survival and recurrence in localized melanoma: a multivariate approach. World J Surg 1992;16(2):191–5. Cross Ref link Pubmed link
  • 224  Breslow A. Thickness, cross‐sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970;172(5):902–8. Cross Ref link Pubmed link
  • 225  Breslow A. Tumor thickness, level of invasion and node dissection in stage I cutaneous melanoma. Ann Surg 1975;182(5):572–5. Cross Ref link Pubmed link
  • 226  Barnhill RL, Fine JA, Roush GC, Berwick M. Predicting five‐year outcome for patients with cutaneous melanoma in a population‐based study. Cancer 1996;78(3):427–32. Cross Ref link Pubmed link
  • 227  McCarthy WH, Shaw HM, Thompson JF, Milton GW. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow‐up study. Surg Gynecol Obstet 1988;166(6):497–502. Pubmed link
  • 228  Balch CM, Soong SJ, Murad TM, et al. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 1981;193(3):377–88. Cross Ref link Pubmed link
  • 229  Elder DE, Guerry D 4th, VanHorn M, et al. The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51–3.99 mm). Cancer 1985;56(2):413–18. Cross Ref link Pubmed link
  • 230  Schmoeckel C, Braun‐Falco O. Prognostic index in malignant melanoma. Arch Dermatol 1978;114(6):871–3. Cross Ref link Pubmed link
  • 231  Schmoeckel C, Bockelbrink A, Bockelbrink H, Braun‐Falco O. Low‐ and high‐risk malignant melanoma – II. Multivariate analyses for a prognostic classification. Eur J Cancer Clin Oncol 1983;19(2):237–43. Cross Ref link Pubmed link
  • 232  Gimotty PA, Elder DE, Fraker DL, et al. Identification of high‐risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 2007;25(9):1129–34. Cross Ref link Pubmed link
  • 233  Busam KJ. The prognostic importance of tumor mitotic rate for patients with primary cutaneous melanoma. Ann Surg Oncol 2004;11(4):360–1. Cross Ref link Pubmed link
  • 234  Eggermont AM, Suciu S, Testori A, et al. Long‐term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa‐2b versus observation in resected stage III melanoma. J Clin Oncol 2012;30(31):3810–18. Cross Ref link Pubmed link
  • 235  Egger ME, Gilbert JE, Burton AL, et al. Lymphovascular invasion as a prognostic factor in melanoma. Am Surg 2011;77(8):992–7. Pubmed link
  • 236  Clark WH Jr, Elder DE, Guerry D 4th, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;Dec 20;81(24):1893–904. Cross Ref link Pubmed link
  • 237  Morton DL, Davtyan DG, et al. Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness. Cancer 1993;71:3737. Cross Ref link Pubmed link
  • 238  O'Brien CJ, Coates AS, Petersen‐Schaefer K, et al. Experience with 998 cutaneous melanomas of the head and neck over 30 years. Am J Surg 1991;Oct;162(4):310–14. Cross Ref link Pubmed link
  • 239  Garbe C, Büttner P, Bertz J, et al. Primary cutaneous melanoma. Prognostic classification of anatomic location. Cancer 1995;May 15;75(10):2492–8. Cross Ref link Pubmed link
  • 240  Austin PF, Cruse CW, Lyman G, et al. Age as a prognostic factor in the malignant melanoma population. Ann Surg Oncol 1994;1(6):487–94. Cross Ref link Pubmed link
  • 241  Shaw HM, McGovern VJ, Milton GW, et al. Histologic features of tumors and the female superiority in survival from malignant melanoma. Cancer 1980;45(7):1604–8. Cross Ref link Pubmed link
  • 242  Balch CM, Soong SJ, Shaw HM, et al. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ, eds. Cutaneous Melanoma, 2nd edn. Philadelphia: Lippincott, 1992:165–87.
  • 243  Morton DL, Thompson JF, Cochran AJ, et al. Sentinel‐node biopsy or nodal observation in melanoma. N Engl J Med 2006;Sep 28;355(13):1307–17. Cross Ref link Pubmed link
  • 244  Mocellin S, Hoon DS, Pilati P, et al. Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta‐analysis of prognosis. J Clin Oncol 2007;25(12):1588–95. Cross Ref link Pubmed link
  • 245  Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel‐node biopsy versus nodal observation in melanoma. N Engl J Med 2014;Feb 13;370(7):599–609. Cross Ref link Pubmed link
  • 246  Maza S, Valencia R, Geworski L, et al. Influence of fast lymphatic drainage on metastatic spread in cutaneous malignant melanoma: a prospective feasibility study. Eur J Nucl Med Mol Imaging 2003;30(4):538–44. Cross Ref link Pubmed link
  • 247  Mahieu‐Renard L, Cammilleri S, Giorgi R, et al. Slow dynamics of lymphoscintigraphic mapping is associated to the negativity of the sentinel node in melanoma patients. Ann Surg Oncol 2008;15(10):2878–86. Cross Ref link Pubmed link
  • 248  Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27(36):6199–206. Cross Ref link Pubmed link
  • 249  Van der Leest RJ, Liu L, Coebergh JW, et al. Risk of second primary in situ and invasive melanoma in a Dutch population‐based cohort: 1989–2008. Br J Dermatol 2012;D;167(6):1321–30. Cross Ref link Pubmed link
  • 250  Romano E, Scordo M, Dusza SW, et al. Site and timing of first relapse in stage III melanoma patients: implications for follow‐up guidelines. J Clin Oncol 2010;28:3042–7. Cross Ref link Pubmed link
  • 251  Fong ZV, Tanabe KK. Comparison of melanoma guidelines in the U.S.A., Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review. Br J Dermatol 2014;170:20–30. Cross Ref link Pubmed link
  • 1  Schwartz JL, Wang TS, Hamilton TA, Lowe L, Sondak VK, Johnson TM. Thin primary cutaneous melanomas: associated detection patterns, lesion characteristics, and patient characteristics. Cancer 2002 Oct 1;95(7):1562–8. Cross Ref link Pubmed link
  • 2  Liu W, Hill D, Gibbs AF, et al. What features do patients notice that help to distinguish between benign pigmented lesions and melanomas? The ABCD(E) rule versus the seven‐point checklist. Melanoma Res 2005 Dec;15(6):549–54. Cross Ref link Pubmed link
  • 3  Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: the role of physician examination and self‐examination of the skin. Cancer J Clin 1985 May–Jun;35(3):130–51. Cross Ref link
  • 4  Abbasi NR, Shaw HM, Rigel DS, et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA 2004 Dec 8;292(22):2771–6. Cross Ref link Pubmed link
  • 5  Gachon J, Beaulieu P, Sei JF, et al. First prospective study of the recognition process of melanoma in dermatological practice. Arch Dermatol 2005 Apr;141(4):434–8. Cross Ref link Pubmed link
  • 6  Molenkamp BG, Sluijter BJ, Oosterhof B, Meijer S, van Leeuwen PA. Non‐radical diagnostic biopsies do not negatively influence melanoma patient survival. Ann Surg Oncol 2007 Apr;14(4):1424–30. Cross Ref link Pubmed link
  • 7  Karimipour DJ, Schwartz JL, Wang TS, et al. Microstaging accuracy after subtotal incisional biopsy of cutaneous melanoma. J Am Acad Dermatol 2005 May;52(5):798–802. Cross Ref link Pubmed link
  • 8  McGinnis KS, Lessin SR, Elder DE, et al. Pathology review of cases presenting to a multidisciplinary pigmented lesion clinic. Arch Dermatol 2002 May;138(5):617–21. Pubmed link
  • 9  Farmer ER, Gonin R, Hanna MP. Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum Pathol 1996 Jun;27(6):528–31. Cross Ref link Pubmed link
  • 10  Corona R, Mele A, Amini M, et al. Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J Clin Oncol 1996 Apr;14(4):1218–23. Pubmed link
  • 11  Coit DG, Andtbacka R, Anker CJ, et al. Melanoma. J Natl Comp Cancer Network 2012 Mar;10(3):366–400.
  • 12  Veronesi U, Cascinelli N. Narrow excision (1‐cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991 Apr;126(4):438–41. Cross Ref link Pubmed link
  • 13  Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. New Engl J Med 1988 May 5;318(18):1159–62. Cross Ref link Pubmed link
  • 14  Cascinelli N. Margin of resection in the management of primary melanoma. Semin Surg Oncol 1998 Jun;14(4):272–5. Cross Ref link Pubmed link
  • 15  Cohn‐Cedermark G, Rutqvist LE, Andersson R, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2‐cm versus 5‐cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8‐2.0 mm. Cancer 2000 Oct 1;89(7):1495–501. Cross Ref link Pubmed link
  • 16  Balch CM, Soong SJ, Smith T, et al. Long‐term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1‐4 mm melanomas. Ann Surg Oncol 2001 Mar;8(2):101–8. Pubmed link
  • 17  Khayat D, Rixe O, Martin G, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1‐mm thick). Cancer 2003 Apr 15;97(8):1941–6. Cross Ref link Pubmed link
  • 18  Thomas JM, Newton‐Bishop J, A'Hern R, et al. Excision margins in high‐risk malignant melanoma. New Engl J Med 2004 Feb 19;350(8):757–66. Cross Ref link Pubmed link
  • 19  Sladden MJ, Balch C, Barzilai DA, et al. Surgical excision margins for primary cutaneous melanoma. Cochrane Syst Rev 2009 (4):CD004835.
  • 20  Coit DG, Andtbacka R, Anker CJ, et al. Melanoma, version 2. 2013: featured updates to the NCCN guidelines. J Natl Comp Cancer Network 2013 Apr 1;11(4):395–407.
  • 21  Bichakjian CK, Halpern AC, Johnson TM, et al. Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol 2011 Nov;65(5):1032–47. Cross Ref link Pubmed link
  • 22  Guitart J, Lowe L, Piepkorn M, et al. Histological characteristics of metastasizing thin melanomas: a case–control study of 43 cases. Arch Dermatol 2002 May;138(5):603–8. Pubmed link
  • 23  Zalla MJ, Lim KK, Dicaudo DJ, Gagnot MM. Mohs micrographic excision of melanoma using immunostains. Dermatol Surg 2000 Aug;26(8):771–84. Cross Ref link Pubmed link
  • 24  Demirci H, Johnson TM, Frueh BR, Musch DC, Fullen DR, Nelson CC. Management of periocular cutaneous melanoma with a staged excision technique and permanent sections the square procedure. Ophthalmology 2008 Dec;115(12):2295–300 e3. Cross Ref link Pubmed link
  • 25  Prieto VG, Argenyi ZB, Barnhill RL, et al. Are en face frozen sections accurate for diagnosing margin status in melanocytic lesions? Am J Clin Pathol 2003 Aug;120(2):203–8. Cross Ref link Pubmed link
  • 26  Phan GQ, Messina JL, Sondak VK, Zager JS. Sentinel lymph node biopsy for melanoma: indications and rationale. Cancer Control 2009 Jul;16(3):234–9. Pubmed link
  • 27  Ross MI, Gershenwald JE. Sentinel lymph node biopsy for melanoma: a critical update for dermatologists after two decades of experience. Clin Dermatol 2013 May–Jun;31(3):298–310. Cross Ref link Pubmed link
  • 28  Veronesi U, Adamus J, Bandiera DC, et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 1977 Sep 22;297(12):627–30. Cross Ref link Pubmed link
  • 29  Sim FH, Taylor WF, Pritchard DJ, Soule EH. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc 1986 Sep;61(9):697–705. Cross Ref link Pubmed link
  • 30  Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998 Mar 14;351(9105):793–6. Cross Ref link Pubmed link
  • 31  Balch CM, Soong S, Ross MI, et al. Long‐term results of a multi‐institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000 Mar;7(2):87–97. Cross Ref link Pubmed link
  • 32  Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992 Apr;127(4):392–9. Cross Ref link Pubmed link
  • 33  Thompson JF, McCarthy WH, Bosch CM, et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995 Aug;5(4):255–60. Cross Ref link Pubmed link
  • 34  Ross MI, Reintgen D, Balch CM. Selective lymphadenectomy: emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol 1993 May–Jun;9(3):219–23. Pubmed link
  • 35  Valsecchi ME, Silbermins D, de Rosa N, Wong SL, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta‐analysis. J Clin Oncol 2011 Apr 10;29(11):1479–87. Cross Ref link Pubmed link
  • 36  de Rosa N, Lyman GH, Silbermins D, et al. Sentinel node biopsy for head and neck melanoma: a systematic review. Otolaryngol Head Neck Surg 2011 Sep;145(3):375–82. Cross Ref link Pubmed link
  • 37  Stoffels I, Boy C, Poppel T, et al. Association between sentinel lymph node excision with or without preoperative SPECT/CT and metastatic node detection and disease‐free survival in melanoma. JAMA 2012 Sep 12;308(10):1007–14. Cross Ref link Pubmed link
  • 38  Durham AB, Wong SL. Sentinel lymph node biopsy in melanoma: controversies and current guidelines. Future Oncol 2014 Feb;10(3):429–42. Cross Ref link Pubmed link
  • 39  Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma. European consensus‐based interdisciplinary guideline – Update 2012. Eur J Cancer 2012 Oct;48(15):2375–90. Cross Ref link Pubmed link
  • 40  Garbe C, Hauschild A, Volkenandt M, et al. Evidence and interdisciplinary consensus‐based German guidelines: surgical treatment and radiotherapy of melanoma. Melanoma Res 2008 Feb;18(1):61–7. Cross Ref link Pubmed link
  • 41  Australian Cancer Network Melanoma Guidelines Revision Working Party (Party ACNMGRW). Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand. Wellington: Cancer Council Australia and Australian Cancer Network, Sydney and New Zealand Guidelines Group, 2008 http://www.cancer.org.au/content/pdf/HealthProfessionals/ClinicalGuidelines/ClinicalPracticeGuidelines‐ManagementofMelanoma.pdf (last accessed August 2015).
  • 42  Wong SL, Balch CM, Hurley P, et al. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol 2012 Aug 10;30(23):2912–18. Cross Ref link Pubmed link
  • 43  Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel‐node biopsy versus nodal observation in melanoma. N Engl J Med 2014 Feb 13;370(7):599–609. Cross Ref link Pubmed link
  • 44  Morton DL, Thompson JF, Cochran AJ, et al. Sentinel‐node biopsy or nodal observation in melanoma. N Engl J Med 2006 Sep 28;355(13):1307–17. Cross Ref link Pubmed link
  • 45  Faries MB, Thompson JF, Cochran A, et al. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol 2010 Dec;17(12):3324‐9. Cross Ref link Pubmed link
  • 46  Sabel MS, Griffith KA, Arora A, et al. Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy. Surgery 2007 Jun;141(6):728–35. Cross Ref link Pubmed link
  • 47  Puleo CA, Messina JL, Riker AI, et al. Sentinel node biopsy for thin melanomas: which patients should be considered? Cancer Control 2005 Oct;12(4):230–5. Pubmed link
  • 48  Andtbacka RH, Gershenwald JE. Role of sentinel lymph node biopsy in patients with thin melanoma. J Natl Comp Cancer Network 2009 Mar;7(3):308–17.
  • 49  Murali R, Haydu LE, Quinn MJ, et al. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma. Ann Surg 2012 Jan;255(1):128–33. Cross Ref link Pubmed link
  • 50  Wong SL. The role of sentinel lymph node biopsy in the management of thin melanoma. Am J Surg 2005 Aug;190(2):196–9. Cross Ref link Pubmed link
  • 51  Bleicher RJ, Essner R, Foshag LJ, Wanek LA, Morton DL. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol 2003 Apr 1;21(7):1326–31. Cross Ref link Pubmed link
  • 52  Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009 Dec 20;27(36):6199–206. Cross Ref link Pubmed link
  • 53  Morton DL. Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT‐I and MSLT‐II) in melanoma. Clin Exp Metastasis 2012 Oct;29(7):699–706. Cross Ref link Pubmed link
  • 54  van der Ploeg AP, van Akkooi AC, Verhoef C, Eggermont AM. Completion lymph node dissection after a positive sentinel node: no longer a must? Curr Opin Oncol 2013 Mar;25(2):152–9. Cross Ref link Pubmed link
  • 1  Dummer R, Mangana J. Long‐term pegylated interferon‐alpha and its potential in the treatment of melanoma. Biologics 2009;3:169–82. Pubmed link
  • 2  Grob JJ, Dreno B, de la Salmoniere P, et al. Randomised trial of interferon alpha‐2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998 Jun 27;351(9120):1905–10. Cross Ref link Pubmed link
  • 3  Eggermont AM, Suciu S, Testori A, et al. Long‐term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa‐2b versus observation in resected stage III melanoma. J Clin Oncol 2012 Nov 1;30(31):3810–18. Cross Ref link Pubmed link
  • 4  Kirkwood JM, Ibrahim JG, Sondak VK, et al. High‐ and low‐dose interferon alfa‐2b in high‐risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000 Jun;18(12):2444–58. Pubmed link
  • 5  Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa‐2b adjuvant therapy of high‐risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996 Jan;14(1):7–17. Pubmed link
  • 6  Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high‐risk melanoma: a systematic review and meta‐analysis. J Natl Cancer Inst 2010 Apr 7;102(7):493–501. Cross Ref link Pubmed link
  • 7  Eggermont AM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa‐2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008 Jul 12;372(9633):117–26. Cross Ref link Pubmed link
  • 8  Kleeberg UR, Suciu S, Brocker EB, et al. Final results of the EORTC 18871/DKG 80‐1 randomised phase III trial. rIFN‐alpha2b versus rIFN‐gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high‐risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 2004 Feb;40(3):390–402. Cross Ref link Pubmed link
  • 9  Oberholzer PA, Kee D, Dziunycz P, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012 Jan 20;30(3):316–21. Cross Ref link Pubmed link
  • 10  Su Y, Vilgelm AE, Kelley MC, et al. RAF265 inhibits the growth of advanced human melanoma tumors. Clin Cancer Res 2012 Apr 15;18(8):2184–98. Cross Ref link Pubmed link
  • 11  Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 2012 Jul 1;30(19):2375–83. Cross Ref link Pubmed link
  • 12  Lens MB, Dawes M. Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials. Lancet Oncol 2003 Jun;4(6):359–64. Cross Ref link Pubmed link
  • 13  Boesch CE, Meyer T, Waschke L, et al. Long‐term outcome of hyperthermic isolated limb perfusion (HILP) in the treatment of locoregionally metastasised malignant melanoma of the extremities. Int J Hyperthermia 2010 Feb;26(1):16–20. Cross Ref link Pubmed link
  • 14  Hong A, Fogarty G. Role of radiation therapy in cutaneous melanoma. Cancer J 2012 Mar–Apr;18(2):203–7. Cross Ref link Pubmed link
  • 15  Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph‐node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 2012 Jun;13(6):589–97. Cross Ref link Pubmed link
  • 16  Mali B, Jarm T, Snoj M, Sersa G, Miklavcic D. Antitumor effectiveness of electrochemotherapy: a systematic review and meta‐analysis. Eur J Surg Oncol 2013 Jan;39(1):4–16. Cross Ref link Pubmed link
  • 17  Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide‐ or tumor lysate‐pulsed dendritic cells. Nat Med 1998 Mar;4(3):328–32. Cross Ref link Pubmed link
  • 18  Goldinger SM, Dummer R, Baumgaertner P, et al. Nano‐particle vaccination combined with TLR‐7 and ‐9 ligands triggers memory and effector CD8(+) T‐cell responses in melanoma patients. Eur J Immunol 2012 Nov;42(11):3049–61. Cross Ref link Pubmed link
  • 19  Hodi FS, Lee J, McDermott DF, et al. Multicenter, randomized phase II trial of GM‐CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608. J Clin Oncol 2013;31(Suppl.; abstr. CRA9007). Cross Ref link
  • 20  Dong H, Strome SE, Salomao DR, et al. Tumor‐associated B7‐H1 promotes T‐cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002 Aug;8(8):793–800. Cross Ref link Pubmed link
  • 21  Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012 Apr;12(4):252–64. Cross Ref link Pubmed link
  • 22  Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti‐PD‐1 antibody in cancer. N Engl J Med 2012 Jun 28;366(26):2443–54. Cross Ref link Pubmed link
  • 23  Brahmer JR. PD‐1‐targeted immunotherapy: recent clinical findings. Clin Adv Hematol Oncol 2012 Oct;10(10):674–5. Pubmed link
  • 24  Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti‐PD‐1) in melanoma. N Engl J Med 2013 Jul 11;369(2):134–44. Cross Ref link Pubmed link
  • 25  Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013 Jul 11;369(2):122–33. Cross Ref link Pubmed link
  • 26  Atkins MB, Lotze MT, Dutcher JP, et al. High‐dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17(7):2105–16. Pubmed link
  • 27  Petrella T, Quirt I, Verma S, et al. Single‐agent interleukin‐2 in the treatment of metastatic melanoma. Curr Oncol 2007;14(1):21–6. Cross Ref link Pubmed link
  • 28  Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011 Jun 30;364(26):2507–16. Cross Ref link Pubmed link
  • 29  Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010 Aug 26;363(9):809–19. Cross Ref link Pubmed link
  • 30  Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF‐mutant melanoma metastatic to the brain (BREAK‐MB): a multicentre, open‐label, phase 2 trial. Lancet Oncol 2012 Nov;13(11):1087–95. Cross Ref link Pubmed link
  • 31  Pratilas CA, Taylor BS, Ye Q, et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF‐MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A 2009 Mar 17;106(11):4519–24. Cross Ref link Pubmed link
  • 32  Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF‐mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013 Feb 1;31(4):482–9. Cross Ref link Pubmed link
  • 33  Kirkwood JM, Bastholt L, Robert C, et al. Phase II, open‐label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012 Jan 15;18(2):555–67. Cross Ref link Pubmed link
  • 34  Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non‐randomised, open‐label phase 2 study. Lancet Oncol 2013 Mar;14(3):249–56. Cross Ref link Pubmed link
  • 35  Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012 Nov;367(18):1694–703. Cross Ref link Pubmed link
  • 36  Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015;372(1):30–9. Cross Ref link Pubmed link
  • 37  Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF‐mutated melanoma. N Engl J Med 2014;371(20):1867–76. Cross Ref link Pubmed link
  • 38  Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006 Jan 19;439(7074):358–62. Cross Ref link Pubmed link
  • 39  Rinderknecht JD, Goldinger SM, Rozati S, et al. RASopathic skin eruptions during vemurafenib therapy. PLOS One 2013;8(3):e58721. Cross Ref link Pubmed link
  • 40  Anforth RM, Blumetti TC, Kefford RF, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol 2012 Nov;167(5):1153–60. Cross Ref link Pubmed link
  • 41  Dummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 2012 Feb 2;366(5):480–1. Cross Ref link Pubmed link
  • 42  Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF‐mutated metastatic melanoma: a multicentre, open‐label, phase 3 randomised controlled trial. Lancet 2012 Jul 28;380(9839):358–65. Cross Ref link Pubmed link
  • 43  Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small‐molecule mitogen‐activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY‐142886) in patients with advanced cancers. J Clin Oncol 2008 May 1;26(13):2139–46. Cross Ref link Pubmed link
  • 44  Eggmann N, Felderer L, Urner U, et al. Self limiting serous retinopathy‐like toxicity during MEK Kinase inhibition. Poster 32, EADO Meeting Barcelona, November, 2012.
  • 45  Belloni B, Schonewolf N, Rozati S, Goldinger SM, Dummer R. Cutaneous drug eruptions associated with the use of new oncological drugs. Chem Immunol Allergy 2012;97:191–202. Cross Ref link Pubmed link
  • 46  Schad K, Baumann Conzett K, Zipser MC, et al. Mitogen‐activated protein/extracellular signal‐regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. Clin Cancer Res 2010 Feb 1;16(3):1058–64. Cross Ref link Pubmed link
  • 47  Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367(18):1694–703. Cross Ref link Pubmed link
  • 48  Eggermont AM, Suciu S, Testori A, et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 2012;48(2):218–25. Cross Ref link Pubmed link
  • 49  Das Thakur M, Salangsang F, Landman AS, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013 Feb 14;494(7436):251–5. Cross Ref link Pubmed link
  • 50  Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006 Sep 10;24(26):4340–6. Cross Ref link Pubmed link
  • 51  Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011 Jun 8;305(22):2327–34. Cross Ref link Pubmed link
  • 52  Guo J, Si L, Kong Y, et al. Phase II, open‐label, single‐arm trial of imatinib mesylate in patients with metastatic melanoma harboring c‐Kit mutation or amplification. J Clin Oncol 2011 Jul 20;29(21):2904–9. Cross Ref link Pubmed link
  • 53  Carvajal RD, Sosman JA, Quevedo F, et al. Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM). J Clin Oncol 2013;31(Suppl.): Abstr. CRA9003. Cross Ref link
  • 54  Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open‐label, phase 2 trial. Lancet Oncol 2012 May;13(5):459–65. Cross Ref link Pubmed link
  • 55  Dummer R, Goldinger SM, Turtschi C, et al. Open‐label pilot study of vemurafenib in previously treated metastatic melanoma (mm) patients (pts) with symptomatic brain metastases (bm). Ann Oncol 2012; ESMO, Vienna, Abstr. 2720. Pubmed link
  • 56  Quirbt I, Verma S, Petrella T, Bak K, Charette M. Temozolomide for the treatment of metastatic melanoma. Curr Oncol 2007;14(1):27–33. Cross Ref link Pubmed link
  • 57  Gogas H, Polyzos A, Stavrinidis I, et al. Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 2006 Dec;17(12):1835–41. Cross Ref link Pubmed link
  • 58  Sasse AD, Sasse EC, Clark LG, Ulloa L, Clark OA. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev 2007(1):CD005413. Pubmed link
  • 59  Hersh E, Del Vecchio M, Brown M, et al. Phase 3, randomized, open‐label, multicenter trial of nab‐paclitaxel (nab‐P) vs dacarbazine (DTIC) in previously untreated patients with metastatic malignant melanoma (MMM). Pigment Cell Melanoma Res 2012;25(6):863.
  • 60  von Moos R, Seifert B, Simcock M, et al. First‐line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol 2012 Feb;23(2):531–6. Cross Ref link Pubmed link
  • 61  Kim KB, Sosman JA, Fruehauf JP, et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 2012 Jan 1;30(1):34–41. Cross Ref link Pubmed link
  • 62  Ji Z, Flaherty KT, Tsao H. Targeting the RAS pathway in melanoma. Trends Mol Med 2012 Jan;18(1):27–35. Cross Ref link Pubmed link